KR20070096995A - Composition for reducing body fat - Google Patents
Composition for reducing body fat Download PDFInfo
- Publication number
- KR20070096995A KR20070096995A KR1020070088453A KR20070088453A KR20070096995A KR 20070096995 A KR20070096995 A KR 20070096995A KR 1020070088453 A KR1020070088453 A KR 1020070088453A KR 20070088453 A KR20070088453 A KR 20070088453A KR 20070096995 A KR20070096995 A KR 20070096995A
- Authority
- KR
- South Korea
- Prior art keywords
- cla
- oryzanol
- gamma
- ffa
- body fat
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Engineering & Computer Science (AREA)
Abstract
Description
본 발명은 체지방감소용 조성물에 관한 것으로, 특히 인체의 체지방을 감소하기 위한 용도로 사용되기에 적합한 것으로 공액리놀레산(conjugated linoleic acid; CLA)을 포함하는 조성물에 대한 것이다. The present invention relates to a composition for reducing body fat, and in particular, to a composition containing conjugated linoleic acid (CLA), which is suitable for use in reducing body fat in the human body.
CLA는 체지방감소효과를 비롯한 항당뇨효과, 면역증강효과 등의 다양한 효과를 갖는 기능성 물질임이 많은 연구자에 의해 밝혀졌다. 특히 CLA는 지방성분으로서 체지방감소효과 등의 기능성을 갖기 때문에 많은 영양학자들이 관심을 갖게 되었다. CLA는 지방의 합성과 지방산의 ester화를 저해하여 지방세포에 지방의 축적을 감소시키는 결과를 유도하는 것이다. CLA는 다양한 동물실험에서 뿐만 아니라 인체실험에서도 체지방을 감소시키는 것으로 확인되었다.Many researchers have found that CLA is a functional substance with various effects such as body fat reduction effect, anti-diabetic effect and immune enhancing effect. In particular, many nutritionists have been interested in CLA because of its functionality as a body fat reduction effect. CLA inhibits fat synthesis and fatty acid esterification, leading to a decrease in fat accumulation in adipocytes. CLA has been shown to reduce body fat in various animal studies as well as in human testing.
그러나, 이러한 CLA의 체지방 감소 효과는 아직 만족할 만한 수준에 이르지 못하였고, 이에 따라 상기 CLA의 체지방 감소 효과를 증진시키기 위한 연구개발의 필요성은 항시 존재하고 있는 실정이다.However, the body fat reduction effect of the CLA has not yet reached a satisfactory level, and thus, there is always a need for research and development to enhance the body fat reduction effect of the CLA.
이에 본 발명의 목적은 종래에 체지방 감소 효과가 있다고 알려진 CLA의 체지방 감소 기능을 증진시키기 위한 것이다. 즉, 본 발명은 CLA에 감마 오리자놀이나 상기 감마 오리자놀이 함유된 추출물을 포함시킴으로써, 종래의 CLA 또는 감마 오리자놀만으로 이루어진 조성물보다 체지방 감소 기능이 현저히 우수하고, 특히 내장지방을 감소시키는 효과가 탁월한 체지방감소용 조성물을 제공하고자 한다. Accordingly, an object of the present invention is to enhance the body fat reduction function of CLA, which is known to have a body fat reduction effect. That is, the present invention includes a gamma oryzanole or an extract containing the gamma oryzanole in the CLA, so that the body fat reduction function is remarkably superior to the composition consisting of the conventional CLA or gamma oryzanol only, in particular, the effect of reducing visceral fat is excellent To provide a composition for.
상기한 목적을 달성하기 위한 본 발명에 따른 체지방감소용 조성물은 공액리놀레산(conjugated linoleic acid: CLA)과 감마 오리자놀(r-oryzanol)을 포함하는 것을 특징으로 한다. 또한, 본 발명은 공액리놀레산(CLA)과 감마 오리자놀이 함유된 추출물을 포함하는 것을 특징으로 하는 체지방감소용 조성물일 수 있다. Composition for reducing body fat according to the present invention for achieving the above object is characterized in that it comprises a conjugated linoleic acid (CLA) and gamma-orizanol (r-oryzanol). In addition, the present invention may be a composition for reducing body fat, characterized in that it comprises an extract containing conjugated linoleic acid (CLA) and gamma orizol.
종래에 감마 오리자놀은 미강(rice bran), 옥수수, 보리등의 곡물의 배아유에 주로 함유되어있는 것으로 알려진 식물성 생리활성물질로써, 항 혈액응고작용, 항소염작용, 항산화효과, 면역증진작용, 인슐린생성촉진, 신경조절기능, 제지방증가등 여러 가지 기능성을 갖는 것으로 보고되고 있다. 그러나, 본 발명자들은 감마 오리자놀과 CLA의 체지방 감소 기능에 대한 오랜 기간 동안의 연구 끝에, 감마 오리자놀이 CLA의 체지방 감소 기능을 현저히 증가시킨다는 것을 확인함으로써, 본 발명을 완 성하였다. In the past, gamma-orizanol is a physiologically active substance known to be mainly contained in embryonic oils of grains such as rice bran, corn, and barley. It has been reported to have various functions such as palpation, neuromodulation, and lean body mass. However, the inventors have completed the present invention by confirming that after a long time study of the body fat reducing function of gamma oryzanol and CLA, the gamma oryzanol significantly increases the body fat reducing function of CLA.
즉, 본 발명은 체지방감소용 조성물에 대한 것으로, 특히 공액리놀레산(CLA)에 감마 오리자놀이나 상기 감마 오리자놀이 함유된 추출물을 포함하는 것을 특징으로 한다. 이러한 본 발명은 종래에 체지방 감소 효과가 있다고 알려진 CLA의 체지방 감소 효과를 현저히 우수하게 증진시킬 수 있다That is, the present invention relates to a composition for reducing body fat, in particular, characterized in that it comprises an extract containing gamma oryzanole or gamma oryanole in conjugated linoleic acid (CLA). The present invention can significantly enhance the body fat reduction effect of CLA, which is known to have a body fat reduction effect.
상술한 바와 같은 본 발명에 있어서, 상기 공액리놀레산은 유리지방산 CLA(CLA Free-Fatty Acid: CLA FFA) 또는 글리세라이드 CLA(CLA glyceride: CLA G)인 것이 바람직하고, 상기 감마 오리자놀이 함유된 추출물은 감마 오리자놀이 함유된 미강추출물(Rice Bran Extract: RBE)인 것이 더욱 바람직하다. In the present invention as described above, the conjugated linoleic acid is preferably free fatty acid CLA (CLA Free-Fatty Acid: CLA FFA) or glyceride CLA (CLA glyceride: CLA G), the extract containing gamma oryzanole is More preferably, Gamma orizol-containing Rice Bran Extract (RBE) is used.
또한, 상기 공액리놀레산(CLA)과 감마 오리자놀(r-oryzanol)은 30: 0.5~3 범위 내의 중량비로 포함되는 것이 가능하며, 상기 공액리놀레산(CLA)과 감마 오리자놀(r-oryzanol)이 함유된 추출물은 30: 10~60 범위 내의 중량비로 포함되는 것일 수 있다. In addition, the conjugated linoleic acid (CLA) and gamma oryzanol (r-oryzanol) may be included in a weight ratio within the range of 30: 0.5 ~ 3, the extract containing the conjugated linoleic acid (CLA) and gamma oryzanol (r-oryzanol) Silver may be included in the weight ratio within the range of 30: 10 ~ 60.
기타 실시예들의 구체적인 사항들은 상세한 설명 및 도면들에 포함되어 있다. Specific details of other embodiments are included in the detailed description and the drawings.
이상에서 살펴본 바와 같이, 본 발명에 따라 공액리놀레산(conjugated linoleic acid; CLA)에 감마 오리자놀(r-oryzanol)이나 상기 감마 오리자놀이 함유된 추출물을 포함하는 체지방감소용 조성물은, 종래의 CLA 또는 감마 오리자놀만으로 이루어진 조성물 보다 체지방 감소 기능이 현저히 우수하고, 특히 내장지방을 감소시키는 효과가 탁월하다.As described above, according to the present invention, a composition for body fat reduction comprising an extract containing gamma-orizanol or gamma-orizanol in conjugated linoleic acid (CLA) is conventional CLA or gamma-orizanol Body fat reduction function is significantly superior to the composition consisting of only, in particular, the effect of reducing visceral fat is excellent.
이하에서는 본 발명의 바람직한 하나의 실시형태를 첨부된 도면을 참조하여 상세하게 설명하기로 한다. 본 발명은 하기의 실시예에 의하여 보다 더 잘 이해 될 수 있으며, 하기의 실시예는 본 발명의 예시 목적을 위한 것이며, 첨부된 특허청구범위에 의하여 한정되는 보호범위를 제한하고자 하는 것은 아니다.Hereinafter, one preferred embodiment of the present invention will be described in detail with reference to the accompanying drawings. The invention may be better understood by the following examples, which are intended for purposes of illustration of the invention and are not intended to limit the scope of protection defined by the appended claims.
실시예Example 1: One: CLACLA FFAFFA 와 r-And r- oryzanoloryzanol 을 포함하는 조성물 제조Preparation comprising a composition
본 실시예에서는 유리지방산형태의 CLA(CLA FFA)와 감마 오리자놀(r-Oryzanol)이 혼합된 복합제 조성물을 제조하였다. In the present embodiment, a composite composition in which CLA (CLA FFA) and gamma-orizanol in the form of free fatty acid were mixed was prepared.
CLA FFA와 감마 오리자놀의 복합제를 제조하는데 있어서는, 상기 각 구성요소의 함량비를 하기 [표 1]에 나타난 바와 같이 달리하여 제조하였다. 제조방법은 각 제조군별 구성요소의 함량비에 따라 각각의 재료를 칭량하여 교반탱크에 담고, 1시간동안 질소를 주입하면서 실온에서 (15-25℃), 교반기로 (150rpm) 혼합하여 제조 하였다. In preparing a combination of CLA FFA and gamma-orizanol, the content ratio of each component was prepared as shown in the following [Table 1]. The manufacturing method was prepared by weighing each material according to the content ratio of the components of each manufacturing group, put in a stirring tank, mixed with a stirrer (150rpm) at room temperature (15-25 ℃) while injecting nitrogen for 1 hour.
[표 1: CLA FFA와 r-oryzanol의 함량비]Table 1: Contents of CLA FFA and r-oryzanol
실험예Experimental Example 1: One: CLACLA FFAFFA 와 r-And r- oryzanoloryzanol 을 포함하는 조성물의 체지방 감소 효과Body fat reduction effect of the composition containing
본 실험예에서는 CLA FFA와 감마 오리자놀(r-Oryzanol) 복합제의 체지방 감소 증진 효과를 실험하였다. In this experiment, the effects of CLA FFA and gamma-orizanol combination on reducing body fat were examined.
(1) 실험내용(1) Experimental Content
CLA FFA와 감마 오리자놀(r-Oryzanol) 복합제의 체지방감소증진효과를 시험하기 위해 12주령의 ICR 마우스를 온도, 습도 및 자연광에 가까운 조명으로 사료와 물이 충분히 공급되는 사육실에서 적응시킨 다음 시험에 임하였다. 처리내용은 하기 [표 2]와 같으며, 각처리군별로 암 수 각각 5마리씩 한 cage 당 5마리씩을 입실하여 사육하였다. 올리브유군, 감마 오리자놀군, CLA FFA와 감마 오리자놀을 혼합하여 제조한 복합제처리군에 대해 매일 0.1ml을 경구투여하였으며, 사료와 물은 자유로이 섭취하게하였다. 각 처리군별로 서로 다른 량의 CLA FFA와 감마오리자놀을 섭취케 할 경우, 총 지방 섭취량의 차이(섭취칼로리의 차이)로 인해 발생하는 실험오차를 줄이기 위해, 체지방감소에 영향을 미치지 않는 올리브유를 보충하여 1일 섭취량을 동일하게 0.1ml로 하였다. 최초 처리일로부터 30일 후에 내장을 적출하고 내장지방의 축적을 관찰하였으며, 내장지방함량을 측정하였다. 내장지방을 분리한 나머지를 동결건조한 다음, 속시렛방법으로 지방을 추출하고, 체지방함량을 측정하였다. 각처리군별로 체지방함량의 감소 또는 증가율을 계산하였다. To test the effect of CLA FFA and gamma-orizanol combination on reducing body fat, 12-week-old ICR mice were adapted in a feeding room with sufficient feed and water under temperature, humidity and natural light. It was. The contents of the treatment are shown in Table 2 below, and 5 males and 5 females of each male and female were housed in each treatment group. The olive oil group, gamma oryzanol group, CLA FFA and gamma oryzanol were administered orally 0.1ml daily for the combination treatment group, and feed and water were freely ingested. If you take different amounts of CLA FFA and gamma-oryzanol in each treatment group, supplement olive oil that does not affect body fat reduction to reduce the experimental error caused by the difference in total fat intake (difference in intake calories). Daily intake was equal to 0.1ml. After 30 days from the initial treatment, the intestines were removed, the accumulation of visceral fat was observed, and the visceral fat content was measured. After separating the visceral fat and freeze-dried, the fat was extracted by Soxhlet method, body fat content was measured. Reduction or increase rate of body fat content was calculated for each treatment group.
[표 2:CLA FFA와 r-oryzanol 조성물의 실험군]Table 2: Experimental group of CLA FFA and r-oryzanol composition
1 생쥐 한 마리의 평균 몸무게 : 30g 1 mouse average weight: 30g
(2) 실험결과(2) Experiment result
실험결과는 [도 1]과 하기 [표 3]에서 보는 바와 같이 CLA FFA만 처리하거나 감마 오리자놀만을 처리한 군에 비해 CLA FFA와 감마 오리자놀을 혼합하여 제조한 복합제를 처리한 군에서 유의성있는 (p<0.05) 내장지방 감소효과가 나타났다. 하기 [표 4]의 결과와 같이 체지방감소효과에 있어서도 유의성있는 (p<0.05) 감소율을 보였다. Experimental results were significant in the group treated with the composite preparation prepared by mixing CLA FFA and gamma-orizanol as compared to the group treated with CLA FFA or gamma-orizanol only as shown in FIG. 1 and Table 3 below (p). <0.05) visceral fat reduction was shown. As shown in [Table 4], there was a significant (p <0.05) decrease in body fat reduction effect.
[표 3: CLA FFA와 r-Oryzanol 조성물의 내장지방 감소 효과]Table 3: Effects of CLA FFA and r-Oryzanol Composition on Visceral Fat Reduction
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음(서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
[표 4: CLA FFA와 r-Oryzanol 조성물의 체지방 감소 효과]Table 4: Body fat reduction effect of CLA FFA and r-Oryzanol composition
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음(서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
실시예Example 2: 2: CLACLA G와 r- G and r- oryzanoloryzanol 을 포함하는 조성물 제조Preparation comprising a composition
본 실시예에서는 글리세라이드 형태의 CLA(CLA glyceride; CLA G)와 감마 오리자놀 (r-Oryzanol)이 혼합된 복합제 조성물을 제조하였다. In this example, a composite composition of CLA (CLA glyceride; CLA G) and gamma-orizanol (r-Oryzanol) in the glyceride form was prepared.
CLA G와 감마 오리자놀의 복합제를 제조하는데 있어서는, 상기 각 구성요소의 함량비를 하기 [표 5]에 나타난 바와 같이 달리하여 제조하였다. 제조방법은 각 제조군별 구성요소의 함량비에 따라 각각의 재료를 칭량하여 교반탱크에 담고, 1시간동안 질소를 주입하면서 실온에서 (15-25℃), 교반기로 (150rpm) 혼합하여 제조하였다. In the preparation of the combination of CLA G and gamma-orizanol, the content ratio of each component was prepared by differently as shown in the following [Table 5]. The manufacturing method was prepared by weighing each material according to the content ratio of the components of each manufacturing group, put in a stirring tank, and mixed with a stirrer (150rpm) at room temperature (15-25 ℃) while injecting nitrogen for 1 hour.
[표 5: CLA G와 r-oryzanol의 함량비]Table 5: Content Ratio of CLA G and r-oryzanol
실험예Experimental Example 2: 2: CLACLA G와 r- G and r- oryzanoloryzanol 을 포함하는 조성물의 체지방 감소 효과Body fat reduction effect of the composition containing
본 실험예에서는 CLA Glyceride (CLA G)와 감마 오리자놀(r-Oryzanol)을 혼합하여 제조한 복합제의 체지방 감소 증진 효과를 실험하였다.In this experimental example, the effect of increasing the body fat reduction of the complex preparation prepared by mixing CLA Glyceride (CLA G) and gamma oryzanol (r-Oryzanol).
(1) 실험내용(1) Experimental Content
CLA G와 감마 오리자놀(r-Oryzanol)을 혼합하여 제조한 복합제의 체지방감소 증진효과를 시험하기위해 12주령의 ICR 마우스를 온도, 습도 및 자연광에 가까운 조명으로 사료와 물이 충분히 공급되는 사육실에서 적응시킨 다음 시험에 임하였다. 처리내용은 하기 [표 6]과 같으며, 각처리군별로 암 수 각각 5마리씩 한 cage 당 5마리씩을 입실하여 사육하였다. 올리브유군, 감마 오리자놀군, CLA G와 감마 오리자놀을 혼합하여제조한 복합제처리군에 대해 매일 0.1ml을 경구투여하였으며, 사료와 물은 자유로이 섭취하게하였다. 각 처리군별로 서로 다른 량의 CLA G와 감마 오리자놀복합제를 섭취케 할 경우, 총 지방 섭취량 (섭취칼로리)의 차이로 인해 발생하는 실험오차를 줄이기 위해, 체지방감소에 영향을 미치지 않는 올리브유를 보충하여 1일 섭취량을 동일하게 0.1ml로 하였다. 최초 처리일로부터 30일 후에 내장을 적출하고 복부지방의 축적을 관찰하였으며, 내장지방함량을 측정하였다. 내장지방을 분리한 나머지를 동결건조한 다음, 속시렛방법으로 지방을 추출하고, 체지방함량을 측정하였다. 각 처리군별로 체지방함량의 감소 또는 증가율을 계산하였다. To test the body fat-lowering effect of a combination of CLA G and gamma-orizanol, a 12-week-old ICR mouse was adapted in a feeding room with sufficient feed and water with near-temperature, humidity and natural light. And then tested. The contents of the treatment are shown in Table 6 below, and 5 males and 5 females of each male and female were housed in each treatment group. The olive oil group, the gamma oryzanol group, and the combination group prepared by mixing CLA G and gamma oryzanol were administered orally 0.1ml daily, and the feed and water were freely ingested. In case of ingesting different amounts of CLA G and gamma-orizanol complex in each treatment group, supplementing olive oil that does not affect body fat reduction to reduce the experimental error caused by the difference in total fat intake (intake calories) The daily intake was set to 0.1 ml in the same manner. After 30 days from the first treatment day, the viscera were removed, abdominal fat accumulation was observed, and visceral fat content was measured. After separating the visceral fat and freeze-dried, the fat was extracted by Soxhlet method, body fat content was measured. Reduction or increase rate of body fat content was calculated for each treatment group.
[표 6: CLA G와 r-oryzanol 조성물의 실험군]Table 6: Experimental group of CLA G and r-oryzanol composition
(2)실험결과(2) Experimental results
하기 [표 7]과 [표 8]에서 보는 바와 같이 CLA G만 처리하거나 감마 오리자놀(r-Oryzanol) 만을 처리한 군에 비해 CLA G와 감마 오리자놀(r-Oryzanol)을 혼합하여 제조한 복합제를 처리한 군에서 유의성(p<0.05)있는 내장지방 감소효과와 체지방감소효과가 나타났다. As shown in [Table 7] and [Table 8] compared to the group treated with CLA G only or gamma oryzanol (r-Oryzanol) only treated with a composite prepared by mixing CLA G and gamma oryzanol (r-Oryzanol) In one group, significant (p <0.05) visceral fat reduction and body fat reduction were found.
[표 7: CLA G와 r-Oryzanol 조성물의 내장지방 감소 효과]Table 7: Visceral Fat Reduction Effects of CLA G and r-Oryzanol Compositions
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음 (서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
[표 8: CLA G와 r-Oryzanol 조성물의 체지방 감소 효과]Table 8: Effect of CLA G and r-Oryzanol Composition on Body Fat Reduction
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음 (서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
실시예Example 3: 3: CLACLA FFAFFA 와 Wow RBERBE 를 포함하는 조성물 제조Preparation comprising a composition
본 실시예에서는 유리지방산형태의 CLA(CLA FFA)와 감마 오리자놀(r-Oryzanol)이 함유된 미강추출물(RBE)이 혼합된 복합제 조성물을 제조하였다. In this embodiment, a composite composition was prepared in which CLA (CLA FFA) and gamma-orizanol (R-Oryzanol) containing free fatty acids were mixed.
이를 위하여, 먼저 감마 오리자놀(r-Oryzanol)이 함유된 미강추출물을 제조하였다. 즉, 미강 3㎏에 에탄올(발효주정, 95%이상) 9L을 첨가하고, 강하게 흔들어 에탄올과 미강이 골고루 섞이게 했다. 그런 다음, 36시간동안 실온 (20~25℃)에서 방치한 후, 여과하여 에탄올을 감압증류하여 제거하였다. 감압농축후 상층과 하층 2개의 층으로 분리되고, 2-4%의 감마 오리자놀을 함유하는 상층을 감마 오리자놀 함유 미강추출물(Rice Bran Extract; RBE)로 사용하였다. To this end, first, rice bran extract containing gamma-orizanol (r-Oryzanol) was prepared. That is, 9 L of ethanol (fermented alcohol, 95% or more) was added to 3 kg of rice bran, and shaken vigorously to mix ethanol and rice bran evenly. Then, the mixture was left at room temperature (20-25 ° C.) for 36 hours, and then filtered to remove ethanol under reduced pressure. After decompression concentration, the upper layer and the lower layer were separated into two layers, and the upper layer containing 2-4% of gamma-orizanol was used as a Gamma-orizanol-containing Rice Bran Extract (RBE).
CLA FFA와 RBE의 복합제를 제조하는데 있어서는, 상기 각 구성요소의 함량비를 하기 [표 9]에 나타난 바와 같이 달리하여 제조하였다. 제조방법은 각 제조군별 구성요소의 함량비에 따라 각각의 재료를 칭량하여 교반탱크에 담고, 1시간동안 질소를 주입하면서 실온에서 (15-25℃), 교반기로 (150rpm) 혼합하여 제조하였다. In preparing the composite agent of CLA FFA and RBE, the content ratio of each component was prepared as shown in the following [Table 9]. The manufacturing method was prepared by weighing each material according to the content ratio of the components of each manufacturing group, put in a stirring tank, and mixed with a stirrer (150rpm) at room temperature (15-25 ℃) while injecting nitrogen for 1 hour.
[표 9: CLA FFA와 RBE의 함량비]Table 9: Content Ratio of CLA FFA and RBE
실험예Experimental Example 3: 3: CLACLA FFAFFA 와 Wow RBERBE 를 포함하는 조성물의 체지방 감소 효과Body fat reduction effect of the composition containing
본 실험예에서는 CLA FFA와 감마 오리자놀함유 미강추출물(RBE)을 혼합하여 제조한 복합제의 체지방 감소 증진 효과를 실험하였다.In this experimental example, the effect of increasing the body fat reduction of the composite prepared by mixing CLA FFA and gamma oryzanol-containing rice bran extract (RBE) was tested.
(1) 실험내용(1) Experimental Content
CLA FFA와 RBE를 혼합하여 제조한 복합제의 체지방감소효과를 시험하기위해 12주령의 ICR 마우스를 온도, 습도 및 자연광에 가까운 조명으로 사료와 물이 충분히 공급되는 사육실에서 적응시킨 다음 시험에 임하였다. 처리내용은 하기 [표 10]과 같으며, 각처리군별로 암 수 각각 5마리씩 한 cage 당 5마리씩을 입실하여 사육하였다. 올리브유군, RBE군, CLA FFA와 RBE를 혼합하여 제조한 복합제처리군에 대해 매일 0.1ml을 경구투여하였으며, 사료와 물은 자유로이 섭취하게하였다. 각 처리군별로 서로 다른 량의 CLA FFA와 RBE 복합제를 섭취케 할 경우, 총 지방 섭취량 (섭취칼로리)의 차이로 인해 발생하는 실험오차를 줄이기 위해, 체지방감소에 영향을 미치지 않는 올리브유를 보충하여 1일 섭취량을 동일하게 0.1ml로 하였다. 최초 처리일로부터 30일만에 내장을 적출하고 복부지방의 축적을 관찰하였으며, 내장지방함량을 측정하였다. 체지방량은 내장지방을 분리한 나머지를 동결건조한 다 음, 속시렛방법으로 지방을 추출하고, 체지방함량을 측정하였다. 각처리군별로 체지방함량의 감소 또는 증가율을 계산하였다. To test the body fat reduction effect of a combination of CLA FFA and RBE, 12-week-old ICR mice were acclimated in a feeding room with enough feed and water under temperature, humidity and natural light. The contents of the treatment are shown in Table 10 below. Five males and five females of each male and female were collected and housed in each cage. The olive oil group, RBE group, CLA FFA and RBE was combined orally administered 0.1ml daily for the combined treatment group, feed and water was freely ingested. If you take different amounts of CLA FFA and RBE combinations for each treatment group, supplement olive oil that does not affect body fat loss to reduce the experimental error caused by the difference in total fat intake (intake calories). The daily intake was equally 0.1 ml. The intestines were removed and the abdominal fats were accumulated and the visceral fat content was measured 30 days after the initial treatment. The fat mass was lyophilized after separating visceral fat, and then fat was extracted by Soxhlet method and body fat content was measured. Reduction or increase rate of body fat content was calculated for each treatment group.
[표 10:CLA FFA와 RBE 조성물의 실험군]Table 10: Experimental group of CLA FFA and RBE compositions
1 생쥐 한 마리의 평균 몸무게 : 30g 1 mouse average weight: 30g
2 감마 오리자놀 0.5mg 함유 2 Gamma Orizanol 0.5mg
3 감마 오리자놀 1.0mg 함유 3 Gamma Oryzanol 1.0mg
4 감마 오리자놀 1.5mg 함유 4 gamma oryzanol containing 1.5mg
5 감마 오리자놀 3.0mg 함유 5 Gamma Orizanol 3.0mg
(2)실험결과(2) Experimental results
하기 [표 11]과 [표 12]에서 보는 바와 같이 CLA FFA만 처리하거나 미강추출물(RBE)만을 처리한 군에 비해 CLA FFA와 미강추출물 (RBE)를 혼합하여제조한 복합 제를 처리한 군에서 유의성(p<0.05)있는 내장지방 감소효과와 체지방감소효과가 나타났다. As shown in [Table 11] and [Table 12] in the group treated with a composite agent prepared by mixing CLA FFA and rice bran extract (RBE) compared to the group treated with CLA FFA only or treated with rice bran extract (RBE) only. Significant (p <0.05) visceral fat reduction and body fat reduction were found.
[표 11: CLA FFA와 RBE 조성물의 내장지방 감소 효과][Table 11: Visceral Fat Reduction Effects of CLA FFA and RBE Compositions]
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음 (서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
[표 12: CLA FFA와 RBE 조성물의 체지방 감소 효과]Table 12: Body fat reduction effect of CLA FFA and RBE composition
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음 (서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
실시예Example 4: 4: CLACLA G와 G and RBERBE 를 포함하는 조성물 제조Preparation comprising a composition
본 실시예에서는 글리세라이드 형태의 CLA(CLA glyceride; CLA G)와 감마 오리자놀(r-Oryzanol)이 함유된 미강추출물(RBE)이 혼합된 복합제 조성물을 제조하였다. In this embodiment, a composite composition was prepared in which glyceride-type CLA (CLA glyceride; CLA G) and gamma-orizanol (r-Oryzanol) containing rice bran extract (RBE) were mixed.
여기서, 감마 오리자놀(r-Oryzanol)이 함유된 미강추출물은 상기 실시예 3에서와 같이 준비하였다. Here, the rice bran extract containing gamma-orizanol (r-Oryzanol) was prepared as in Example 3.
CLA G와 RBE의 복합제를 제조하는데 있어서는, 상기 각 구성요소의 함량비를 하기 [표 13]에 나타난 바와 같이 달리하여 제조하였다. 제조방법은 각 제조군별 구성요소의 함량비에 따라 각각의 재료를 칭량하여 교반탱크에 담고, 1시간동안 질소를 주입하면서 실온에서 (15-25℃), 교반기로 (150rpm) 혼합하여 제조하였다. In the preparation of the composite of CLA G and RBE, the content ratio of each component was prepared by differently as shown in the following [Table 13]. The manufacturing method was prepared by weighing each material according to the content ratio of the components of each manufacturing group, put in a stirring tank, and mixed with a stirrer (150rpm) at room temperature (15-25 ℃) while injecting nitrogen for 1 hour.
[표 13: CLA G와 RBE의 함량비]Table 13: Content Ratio of CLA G and RBE
실험예Experimental Example 4: 4: CLACLA G와 G and RBERBE 를 포함하는 조성물의 체지방 감소 효과Body fat reduction effect of the composition containing
본 실험예에서는 CLA 글리세라이드(CLA G)와 감마 오리자놀 함유 소재 미강추출물(RBE)의 복합제의 체지방 감소 증진 효과를 실험하였다. In this experimental example, the effect of reducing the body fat of the combination of CLA glyceride (CLA G) and gamma oryzanol-containing rice bran extract (RBE) was tested.
(1) 실험내용(1) Experimental Content
CLA G와 RBE의 체지방감소증진효과를 시험하기위해 12주령의 ICR 마우스를 온도, 습도 및 자연광에 가까운 조명으로 사료와 물이 충분히 공급되는 사육실에서 적응시킨 다음 시험에 임하였다. 처리내용은 하기 [표 14]와 같으며, 각처리군별로 암 수 각각 5마리씩 한 cage 당 5마리씩을 입실하여 사육하였다. 올리브유군, RBE군, CLA G와 RBE복합제처리군에 대해 매일 0.1ml을 경구투여하였으며, 사료와 물은 자유로이 섭취하게하였다. 각 처리군별로 서로 다른 량의 CLA G와 RBE를 혼합하여 제조한 복합제를 섭취케 할 경우, 총 지방 섭취량 (칼로리섭취량)의 차이로 인해 발생하는 실험오차를 줄이기 위해, 체지방감소에 영향을 미치지 않는 올리브유를 보충하여 1일 섭취량을 동일하게 0.1ml로 하였다. 최초 처리일로부터 30일 후에 내장을 적출하고 복부지방의 축적을 관찰하였으며, 내장지방함량을 측정하였다. 내장지방을 분리한 나머지를 동결건조한 다음, 속시렛방법으로 지방을 추출하고, 체지방함량을 측정하였다. 각처리군별로 체지방함량의 감소 또는 증가율을 계산하였다. To test the effect of CLA G and RBE on reducing body fat, 12-week-old ICR mice were acclimated in a feeding room with sufficient feed and water under temperature, humidity and natural light. The contents of the treatment are shown in Table 14 below. Five males and five females of each male and female were entered and bred. The olive oil group, RBE group, CLA G and RBE complex group were administered orally 0.1ml daily, and feed and water were freely ingested. In case of taking a combination product made by mixing different amounts of CLA G and RBE for each treatment group, it does not affect body fat reduction in order to reduce the experimental error caused by the difference in total fat intake (calorie intake). Olive oil was supplemented to make the daily intake equal to 0.1 ml. After 30 days from the first treatment day, the viscera were removed, abdominal fat accumulation was observed, and visceral fat content was measured. After separating the visceral fat and freeze-dried, the fat was extracted by Soxhlet method, body fat content was measured. Reduction or increase rate of body fat content was calculated for each treatment group.
[표 14:CLA G와 RBE 조성물의 실험군]Table 14: Experimental group of CLA G and RBE compositions
1 생쥐 한 마리의 평균 몸무게 : 30g 1 mouse average weight: 30g
2 감마 오리자놀 0.5mg 함유 2 Gamma Orizanol 0.5mg
3 감마 오리자놀 1.0mg 함유 3 Gamma Oryzanol 1.0mg
4 감마 오리자놀 1.5mg 함유 4 gamma oryzanol containing 1.5mg
5 감마 오리자놀 3.0mg 함유 5 Gamma Orizanol 3.0mg
(2)실험결과(2) Experimental results
하기 [표 15]와 [표 16]에서 보는 바와 같이 CLA G만 처리하거나 RBE만을 처리한 군에 비해 CLA G와 RBE를 혼합하여 제조한 복합제를 처리한 군에서 유의성(p<0.05)있는 내장지방 감소효과와 체지방감소효과가 나타났다. As shown in [Table 15] and [Table 16], visceral fat having a significant (p <0.05) in the group treated with the composite preparation prepared by mixing CLA G and RBE compared to the CLA G-treated or RBE-only group. Reducing effect and body fat reduction effect were shown.
[표 15: CLA G와 RBE 조성물의 내장지방 감소 효과]Table 15: Visceral Fat Reduction Effects of CLA G and RBE Compositions
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음(서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
[표 16: CLA G와 RBE 조성물의 체지방 감소 효과]Table 16: Body fat reduction effect of CLA G and RBE composition
통계처리: Duncan의 다중검정에의한 0.05% 유의차가있음(서로 다른 소문자로 표시된 군의 평군치는 유의차가있음)Statistical treatment: There was a 0.05% significant difference by Duncan's multiple test (the average value of groups in different lowercase letters was significant)
한편, 상기에서는 본 발명을 특정의 바람직한 실시예에 관련하여 도시하고 설명하였지만, 이하의 특허청구범위에 의해 마련되는 본 발명의 기술적 특징이나 분야를 이탈하지 않는 한도 내에서 본 발명이 다양하게 개조 및 변화될 수 있다는 것은 당업계에서 통상의 지식을 가진 자에게 명백한 것이다. On the other hand, while the present invention has been shown and described with respect to certain preferred embodiments, the invention is variously modified and modified without departing from the technical features or fields of the invention provided by the claims below It will be apparent to those skilled in the art that such changes can be made.
본 발명에 의하는 경우, 공액리놀레산(CLA)에 감마 오리자놀(r-oryzanol)이나 상기 감마 오리자놀이 함유된 추출물을 포함하는 것을 특징으로 하여, 종래의 CLA보다 현저히 우수한 체지방 감소 기능이 있는 조성물을 제공할 수 있다. According to the present invention, a conjugated linoleic acid (CLA) comprises gamma oryzanol (r-oryzanol) or the extract containing the gamma oryzanol, it provides a composition having a significantly lower body fat reduction function than conventional CLA can do.
도 1은 본 발명에 따른 체지방 감소용 조성물을 처리한 실험군과 이것의 대조군 별 내장지방을 나타내는 사진이다. 1 is a photograph showing the experimental group treated with the composition for reducing body fat according to the present invention and visceral fat for each control group thereof.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070088453A KR100809411B1 (en) | 2007-08-31 | 2007-08-31 | Composition For Reducing Body Fat |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070088453A KR100809411B1 (en) | 2007-08-31 | 2007-08-31 | Composition For Reducing Body Fat |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070096995A true KR20070096995A (en) | 2007-10-02 |
KR100809411B1 KR100809411B1 (en) | 2008-03-05 |
Family
ID=38803572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070088453A KR100809411B1 (en) | 2007-08-31 | 2007-08-31 | Composition For Reducing Body Fat |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100809411B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185088A (en) * | 2013-03-22 | 2014-10-02 | Sunstar Inc | Oral composition, adipocyte differentiation inhibitor, and food and drink |
JP2017222715A (en) * | 2017-09-19 | 2017-12-21 | サンスター株式会社 | Oral composition, adipocyte differentiation inhibitor and food and drink |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101580219B1 (en) * | 2013-11-25 | 2016-01-21 | 대한민국(농촌진흥청장) | Composition Comprising Unsaponifiable Matter of Rice Bran for Anti-obesity Activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE313274T1 (en) * | 1998-05-04 | 2006-01-15 | Natural Asa | COMPOSITIONS OF CONJUGATED LINOLIC ACID ENRICHED WITH ISOMERS |
KR100336644B1 (en) * | 2000-10-23 | 2002-05-16 | 강창환 | The composites of raw-type tea with anti-obese function |
-
2007
- 2007-08-31 KR KR1020070088453A patent/KR100809411B1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014185088A (en) * | 2013-03-22 | 2014-10-02 | Sunstar Inc | Oral composition, adipocyte differentiation inhibitor, and food and drink |
JP2017222715A (en) * | 2017-09-19 | 2017-12-21 | サンスター株式会社 | Oral composition, adipocyte differentiation inhibitor and food and drink |
Also Published As
Publication number | Publication date |
---|---|
KR100809411B1 (en) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hoseinifar et al. | Can dietary jujube (Ziziphus jujuba Mill.) fruit extract alter cutaneous mucosal immunity, immune related genes expression in skin and growth performance of common carp (Cyprinus carpio)? | |
CN1919043A (en) | Chicken feed addictive | |
US20090214684A1 (en) | Method for reducing body weight and improving control of body lipids | |
KR20150055876A (en) | Composition for reducing body-fat and weight | |
CN110447902A (en) | A kind of composition with effect of weight reducing | |
Adenowo et al. | Tiger nut as a functional food, pharmacological and industrial agent: a mini review | |
Basharat et al. | Nutritional and functional profile of carob bean (Ceratonia siliqua): A comprehensive review | |
Yu et al. | Inulin and isomalto-oligosaccharide alleviate constipation and improve reproductive performance by modulating motility-related hormones, short-chain fatty acids, and feces microflora in pregnant sows | |
CN102132780A (en) | Feed additive for chickens | |
KR100809411B1 (en) | Composition For Reducing Body Fat | |
CN1919041A (en) | Goose feed addictive | |
KR102192712B1 (en) | An animal feed composition comprising phlorotannin and product for animal | |
CN1919040A (en) | Duck feed addictive | |
EP1627634A1 (en) | Composition for lowering lipid in body | |
CN103315175A (en) | Biogas residue containing chicken formula feed | |
KR101252630B1 (en) | Useful composition for growth and development of children and youths | |
CN103892048B (en) | Piglet is calmed the nerves to increase and exempts from growth-promoting feedstuff additive, preparation method and application thereof | |
KR20100114266A (en) | Dietary composition containing methanol extracts of curcuma longa l. for preventing weightgrain and decreasing blood neutral lipid | |
CN108065078A (en) | A kind of environment-friendly feed additive for reducing weaning stress of piglet syndrome and preparation method and application | |
KR100902947B1 (en) | Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion | |
EP1413208A1 (en) | Health food and antitumor agent | |
CN102919561A (en) | Feed additive for improving weight increasing velocity and immunity of Funiu white goat and preparation method thereof | |
JPH1149690A (en) | Composition for stimulating lipolysis | |
CN105831442A (en) | Anti-stress and growth promoting composite feed additive for pigs | |
CN106135645A (en) | A kind of feed addictive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G15R | Request for early publication | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20130102 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131231 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160224 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170327 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171226 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190226 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20200225 Year of fee payment: 13 |